Special Investigation in Patients With Rheumatoid Arthritis (Combo Study : Adalimumab With High Dose MTX)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Adalimumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms Combo; HAWK
- Sponsors Abbott Japan; AbbVie
- 17 Jul 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
- 17 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 17 Jun 2017 Results (n=346, as of 15 Apr 2016, week 52) assessing long-term safety and effectiveness of adalimumab with higher-dose methotrexate, presented at the 18th Annual Congress of the European League Against Rheumatism.